ImmuPharma: Equity analyst eyes key FDA decision in August

(7:13)

Dimitri Dimitriou on Lupuzor | Immupharma | The New Economy Videos

(7:32)

Stock Surge: GreenPower and ImmuPharma Lead the Charge in Market Gains

(3:10)

ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead

(13:6)

ImmuPharma CEO still open to big pharma deal

(6:6)

ImmuPharma \

(11:39)

Immupharma chairman 'delighted' with first significant investment from specialist US funds

(12:27)

Immupharma PLC assessing best route forward for lead drug Lupuzor

(9:37)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

Sunday Roast-Ben Clube, CEO of #EPP, Shaun Day,Managing Director of #GGP \u0026 Tim McCarthy, CEO of #IMM

(1:40:4)

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

(4:49)

Elite Pharmaceuticals ELTP 2025 Outlook 06Jan2025

(8:8)

Examining Race-Based Medicine | Prioritizing Equity

(58:23)

Sunday Roast-Oliver Friesen,CEO \u0026 Executive Director of #GMET .. #PR1 #POW#AMRQ#IMM#TM1#WBI#GENF#EST

(1:19:18)

Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases

(7:15)

How tariffs could impact pharma and early-stage healthcare investments

(4:21)

Amihud measure explained: liquidity risk of stocks (Excel)

(11:44)

Rheumatoid arthritis - causes, symptoms, diagnosis, treatment, pathology

(12:28)

ImmuPharma chair hails “successful” recruitment for Lupuzor trials

(6:53)

ImmuPharma and Westhaven Gold See Significant Stock Price Surges Amid Market Fluctuations

(5:3)

ImmuPharma expects new Lupozor study to begin in H2 2023

(8:49)

ImmuPharma raise £3.55m 'giving validation' from Lupuzor partner Avion Pharmaceuticals

(8:57)

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

(6:)

Dimitri F Dimitriou, MSC: \

(6:1econd)

ImmuPharma’s McCarthy on phase III Lupuzor trials

(4:35)

Immupharma 'looking forward and planning for success' with Lupuzor

(7:41)

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' Lupuzor licensing deal

(8:51)

ImmuPharma may broaden its collaboration with US partner Avion

(7:44)

ImmuPharma's Dimitriou explains opportunities for Nucant

(4:37)